Subscribe

Rebecca Ahrens-Nicklas, MD, PhD

Articles by Rebecca Ahrens-Nicklas, MD, PhD

Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP

The Implications of the First Successful Personalized Gene Editing Therapy

ByKiran Musunuru, MD, PhD, MPH, ML, MRA,Rebecca Ahrens-Nicklas, MD, PhD,Noah Stansfield

May 22nd 2025

Kiran Musunuru, MD, PhD, and Rebecca Ahrens-Nicklas, MD, PhD, physician-scientists at CHOP, discussed long-term future expectations for personalized gene editing therapy.

Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP

The Next Steps for Personalized Gene Editing

ByRebecca Ahrens-Nicklas, MD, PhD,Kiran Musunuru, MD, PhD, MPH, ML, MRA,Noah Stansfield

May 21st 2025

Rebecca Ahrens-Nicklas, MD, PhD, and Kiran Musunuru, MD, PhD, physician-scientists at CHOP, discussed what lies on the horizon after KJ’s treatment with a CRISPR-based gene editing therapy for CPS1 deficiency.

Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP

Treating CPS1 Deficiency With Personalized Gene Editing

ByKiran Musunuru, MD, PhD, MPH, ML, MRA,Rebecca Ahrens-Nicklas, MD, PhD,Noah Stansfield

May 20th 2025

Kiran Musunuru, MD, PhD, and Rebecca Ahrens-Nicklas, MD, PhD, physician-scientists at CHOP, discussed an n-of-1 clinical trial for a CRISPR gene-editing strategy.

Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP

Rebecca Ahrens-Nicklas, MD, PhD, and Kiran Musunuru, MD, PhD, MPH, ML, MRA, on the Implications of the First Successful Personalized Gene Editing Therapy

ByKiran Musunuru, MD, PhD, MPH, ML, MRA,Rebecca Ahrens-Nicklas, MD, PhD,Noah Stansfield

May 17th 2025

The physician-scientists at CHOP discussed long-term future expectations for personalized gene editing therapy.

Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP

Rebecca Ahrens-Nicklas, MD, PhD, and Kiran Musunuru, MD, PhD, MPH, ML, MRA, on the Next Steps for Personalized Gene Editing

ByKiran Musunuru, MD, PhD, MPH, ML, MRA,Rebecca Ahrens-Nicklas, MD, PhD,Noah Stansfield

May 16th 2025

The physician-scientists at CHOP discussed what lies on the horizon after KJ’s treatment with a CRISPR-based gene editing therapy for CPS1 deficiency.

Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP

Rebecca Ahrens-Nicklas, MD, PhD; and Kiran Musunuru, MD, PhD, MPH, ML, MRA, on Treating CPS1 Deficiency With Personalized Gene Editing

ByKiran Musunuru, MD, PhD, MPH, ML, MRA,Rebecca Ahrens-Nicklas, MD, PhD,Noah Stansfield

May 15th 2025

The physician-scientists at CHOP discussed an n-of-1 clinical trial for a CRISPR gene-editing strategy.

Latest Updated Articles

Rebecca Ahrens-Nicklas, MD, PhD; and Kiran Musunuru, MD, PhD, MPH, ML, MRA, on Treating CPS1 Deficiency With Personalized Gene Editing
Published: May 15th 2025 | Updated:

Trending on CGTlive®

CGTLive®’s Weekly Rewind – October 3, 2025

© 2025 MJH Life Sciences^®

All rights reserved.